Compared to the reference group, the risk of CVD, CAD, PAD, three-point MACE, four-point MACE, and cardiovascular mortality was reduced in the group with genetically predicted lower Lp(a) levels and lifestyle improvements (Fig. 5). The gene discussed is LPA; the disease is coronary artery disorder.